Hyperfine (HYPR) Total Non-Current Liabilities (2022 - 2026)
Hyperfine (HYPR) posted Total Non-Current Liabilities of $26.0 million for Q1 2026, up 82.94% on a QoQ basis from $14.2 million in Q4 2025, and up 152.96% year-over-year from $10.3 million in Q1 2025.
Hyperfine (HYPR) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Hyperfine's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $26.0 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 152.96% year-over-year to $26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.0 million (up 152.96% YoY) and the FY2025 annual result came in at $14.2 million, up 45.06% from the prior year.
- Total Non-Current Liabilities was $26.0 million for Q1 2026 at Hyperfine, up from $14.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $26.0 million in Q1 2026 and bottomed at $9.3 million in Q3 2023.
- A 5-year average of $11.9 million and a median of $10.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 30.35% — and 2026, when it soared 152.96%.
- Hyperfine's Total Non-Current Liabilities stood at $13.3 million in 2022, then dropped by 27.06% to $9.7 million in 2023, then advanced by 0.48% to $9.8 million in 2024, then surged by 45.06% to $14.2 million in 2025, then soared by 82.94% to $26.0 million in 2026.
- Business Quant data shows HYPR's Total Non-Current Liabilities at $26.0 million in Q1 2026, $14.2 million in Q4 2025, and $14.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | 25.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.96 Mn |
| Dec 31, 2025 | 14.19 Mn |
| Sep 30, 2025 | 14.64 Mn |
| Jun 30, 2025 | 10.10 Mn |
| Mar 31, 2025 | 10.26 Mn |
| Dec 31, 2024 | 9.78 Mn |
| Sep 30, 2024 | 11.06 Mn |
| Jun 30, 2024 | 9.85 Mn |
| Mar 31, 2024 | 9.81 Mn |
| Dec 31, 2023 | 9.74 Mn |
| Sep 30, 2023 | 9.30 Mn |
| Jun 30, 2023 | 9.32 Mn |
| Mar 31, 2023 | 9.37 Mn |
| Sep 30, 2022 | 13.35 Mn |
| Jun 30, 2022 | 11.20 Mn |